Compounds > cycloserine
Page last updated: 2024-08-17

cycloserine and Co-infection

cycloserine has been researched along with Co-infection in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, JG; Farley, J; Lancaster, J; Odendaal, R; Shean, K; Van der Walt, M1
Horsburgh, CR; Kvasnovsky, C; Master, I; O'Donnell, MR; Padayatchi, N; Werner, L1
Adebola, SO; Adedeji, TO; Adefuye, BO; Oladeji, SM; Sogebi, OA1

Other Studies

3 other study(ies) available for cycloserine and Co-infection

ArticleYear
Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Resistance, Multiple, Bacterial; Female; Hearing Loss; HIV Infections; Humans; Isoxazoles; Male; Middle Aged; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Prospective Studies; Psychoses, Substance-Induced; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2013
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.
    Emerging infectious diseases, 2013, Volume: 19, Issue:3

    Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Therapy, Combination; Ethambutol; Ethionamide; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pyrazinamide; Retrospective Studies; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult

2013
Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
    Auris, nasus, larynx, 2017, Volume: 44, Issue:4

    Topics: Adult; Age Factors; Aminoglycosides; Antitubercular Agents; Audiometry, Pure-Tone; Body Mass Index; Coinfection; Comorbidity; Cycloserine; Diabetes Mellitus; Female; Hearing Loss; HIV Infections; Humans; Kanamycin; Levofloxacin; Male; Middle Aged; Nigeria; Prospective Studies; Prothionamide; Pyrazinamide; Risk Factors; Time Factors; Tuberculosis, Multidrug-Resistant; Young Adult

2017